Amgen マネジメント
マネジメント 基準チェック /34
Amgenの CEO はBob Bradwayで、 May2012年に任命され、 の在任期間は 14.58年です。 の年間総報酬は$ 24.69Mで、 7.8%給与と92.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.11%を直接所有しており、その価値は$ 205.23M 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と9.3年です。
主要情報
Bob Bradway
最高経営責任者
US$24.7m
報酬総額
| CEO給与比率 | 7.80% |
| CEO在任期間 | 14yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 6.3yrs |
| 取締役会の平均在任期間 | 9.3yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 14
AMGN: Fair Outlook Weighs Pipeline Execution Against Expanded Manufacturing Commitments
Analysts have nudged the Amgen price target slightly lower to about $350. This reflects a modest increase in the discount rate, slightly softer revenue growth assumptions and a small reduction in the future P/E multiple, partly offset by a higher projected profit margin and a mix of recent upgrades, downgrades and price target revisions across the Street.
ナラティブの更新 • Apr 28
AMGN: Recent Rally And Trial Uncertainty Will Pressure Future Returns
Amgen's fair value estimate has moved from about $230.89 to $243.49 as analysts factor in a series of higher price targets from firms across the Street, balanced by several neutral initiations. These initiations point to solid fundamentals but mixed views on potential upside from this level.
新しいナラティブ • Apr 27
Amgen Inc. (AMGN): The Biotech Titan Braces for a MariTide Moment
Amgen Inc. (AMGN) , the global vanguard of innovative biologics and rare disease therapies, enters the final week of April 2026 in a state of high-stakes clinical anticipation.
ナラティブの更新 • Apr 14
AMGN: Diversified Autoimmune And Cardiovascular Pipeline Will Support Future Cash Generation
Analysts have lifted Amgen's average price target, with changes such as the recent $10, $17, $6, $10 and $15 upward revisions reflecting updated views on its pipeline progress, commercial execution, and refreshed financial models. Analyst Commentary Recent Street research on Amgen shows a cluster of higher price targets and fresh coverage that centers on its pipeline, commercial performance, and updated financial models.Seeking Alpha • Apr 07
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
Summary Amgen Inc. is rated a solid Buy, supported by robust revenue growth, pipeline strength, and recent FDA approvals despite looming patent expiries on legacy drugs. Tepezza's successful Phase 3 subcutaneous trial enhances its competitive position in the Thyroid Eye Disease - TED - market, targeting expanded patient access and chronic use. AMGN's 2026 guidance projects $37–$38.4bn in revenue and non-GAAP EPS of $21.6–$23, with a forward P/E of ~17x and a diverse late-stage pipeline. Tepezza may soon face competition from Viridian Therapeutics, Inc.'s veligrotug in TED, which could be approved in June. Viridian also has a subQ TED therapy in Phase 3 studies. While the market has sold VRDN stock on underwhelming clinical data, approvals for both of its assets is not unlikely, helping the company grow its valuation and grow the TED market for itself and AMGN. Read the full article on Seeking Alphaナラティブの更新 • Mar 30
AMGN: Obesity And Cardiovascular Pipeline Will Support Future Cash Generation
Analysts kept the $432 price target for Amgen steady, reflecting a balance between recent target increases tied to pipeline and commercial updates, and newer Hold and Equal Weight initiations that describe the shares as fairly valued after a strong run. Analyst Commentary Recent research on Amgen shows a mix of optimism and caution around valuation, with bullish analysts highlighting commercial execution and the expanding pipeline, while newer initiations frame the shares as fairly valued after a strong move higher.ナラティブの更新 • Mar 16
AMGN: Fair Outlook Balances Patent Expiries With Late Stage Pipeline Potential
The Analyst Price Target for Amgen has been updated from $327.74 to $350.03 as analysts factor in recent price target increases tied to stronger near term commercial execution, added value from key Phase 3 pipeline assets, and a shift toward discounted cash flow based models that emphasize improved margin assumptions and a slightly lower discount rate. Analyst Commentary Recent Street commentary around Amgen reflects a mix of optimism about the current execution and pipeline, alongside ongoing debate about valuation, product risks, and long term earnings durability.ナラティブの更新 • Mar 02
AMGN: Obesity And Cardiovascular Pipeline Will Drive Future Cash Generation
The analyst price target for Amgen in this narrative has moved to $432. Analysts point to updated DCF assumptions, slightly lower revenue growth and profit margin inputs, and a modestly higher future P/E multiple supported by recent price target increases across the Street and ongoing confidence in the pipeline and guidance.ナラティブの更新 • Feb 16
AMGN: Long Patent Expiries And Heavier Spending Will Pressure Future Earnings
Analysts have lifted their price targets on Amgen by about $12 to reflect updated views on fair value, profitability, and future P/E assumptions, while also factoring in a higher discount rate and lower projected revenue growth. Analyst Commentary Recent research on Amgen points to a split view, with several firms lifting price targets while others are turning more cautious.分析記事 • Feb 11
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.52 on 6th of...ナラティブの更新 • Feb 02
AMGN: Obesity And Cardiovascular Pipeline Will Shape Long-Term Cash Generation
Analysts have nudged their Amgen price targets higher by about $10 to $20, citing a shift toward discounted cash flow analysis, steady execution in legacy products, and increased confidence in the obesity and cardiovascular pipeline. Analyst Commentary Recent research on Amgen highlights a wide range of opinions, but there is a clear cluster of bullish analysts who are leaning into higher price targets and more constructive ratings.分析記事 • Jan 21
Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year
Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment on...ナラティブの更新 • Jan 19
AMGN: Obesity And Cardiovascular Pipeline Will Support Long-Term Upside Potential
Analysts have raised their price targets on Amgen into a higher range, with moves such as BofA's shift to a discounted cash flow approach and UBS's upgraded view on earnings and pipeline potential, even as others highlight upcoming patent expiries and spending needs that temper expectations. Analyst Commentary Recent research on Amgen shows a mix of cautious and constructive views, but the price target moves cluster in a higher range, with several firms now anchoring their models around pipeline contributions and cash flow potential alongside the existing portfolio.分析記事 • Jan 07
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 6th of March to $2.52...ナラティブの更新 • Jan 05
AMGN: Patent Expiries And New Drug Launches Will Shape Future Performance
Analysts nudged their fair value estimate for Amgen higher to about $328 per share, up from roughly $323. This reflects slightly firmer revenue expectations and a higher assumed future P/E, balanced against more conservative profit margin assumptions and mixed Street views that highlight both the stability of the core business and uncertainty around patent expiries and new launches.ナラティブの更新 • Dec 15
AMGN: Margin Expansion And Pipeline Progress Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for Amgen higher to approximately $425 from about $405, reflecting a more constructive view on the company as a defensive large cap biotech with improving margin potential and an innovation pipeline that, while still facing patent expiry and execution risks, is increasingly seen as capable of supporting long term earnings power. Analyst Commentary Recent Street research on Amgen highlights a balanced but gradually improving sentiment backdrop, with a growing cohort of bullish analysts positioning the company as a core large cap biotech holding.ナラティブの更新 • Nov 30
AMGN: Future Pipeline Progress And Revenue Diversification Will Shape Performance
Amgen's analyst price target has been raised modestly to $322.88, with analysts citing stable revenue, recent guidance increases, and optimism around its pipeline despite ongoing challenges related to patent expiries. Analyst Commentary Recent Street research provides a nuanced view of Amgen’s valuation, outlook, and potential risk factors, with opinions split between those optimistic about its growth trajectory and those concerned about near-term challenges.ナラティブの更新 • Nov 16
AMGN: Future Pipeline Progress And Profit Margins Will Guide Near-Term Performance
Amgen's fair value target has increased by approximately $7 to $318.51, as analysts highlight robust profit margin improvement and sustained pipeline progress in their latest updates. Analyst Commentary Recent updates from Wall Street reveal a mix of optimism and caution surrounding Amgen’s outlook.分析記事 • Aug 13
Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are
Even though Amgen Inc. ( NASDAQ:AMGN ) posted strong earnings, investors appeared to be underwhelmed. We have done some...分析記事 • Aug 01
Is Amgen (NASDAQ:AMGN) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jun 20
Amgen Inc.'s (NASDAQ:AMGN) Earnings Haven't Escaped The Attention Of Investors
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Seeking Alpha • Apr 17
Amgen: The Biotech That Knows How To Make Money
Summary Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio, with significant contributions from rare disease treatments and biosimilars. Financially robust, Amgen achieved record revenues of $33.4 billion in 2024, with strong EBITDA growth and high free cash flow, despite increased debt from acquisitions. The company's balanced business model and innovative pipeline, including promising drugs in oncology and cardiometabolic diseases, support a "Buy" rating with a 16.44% growth potential. Key risks include expiring patents and regulatory pressures, but Amgen's diversified strategy and strong cash flow position it well for future growth. Read the full article on Seeking Alpha新しいナラティブ • Apr 08
Biosimilar Competition And TEPEZZA Approvals Will Define Future Path
Declining prices combined with biosimilar competition and loss of exclusivity threaten revenue growth and profit margins.新しいナラティブ • Apr 08
Expanding Oncology Portfolio And International Launches Will Unlock Potential
Expansion in oncology and rare diseases, coupled with strategic pipeline innovations, promises substantial long-term revenue and earnings growth.Seeking Alpha • Mar 31
Amgen: Excellent Buy And Hold For A Volatile Market
Summary Amgen is a robust long-term investment due to its strong profitability, competitive moat, and promising pipeline, including an anti-obesity drug. Despite modest short-term growth guidance, AMGN's Horizon Therapeutics acquisition and innovation pipeline offer significant long-term potential. AMGN's 3.1% dividend yield, prudent debt management, and reasonable valuation make it an attractive 'buy and hold' stock. Read the full article on Seeking AlphaSeeking Alpha • Mar 10
Amgen: Riding The MariTide Of Monthly Weight Loss
Summary Amgen Inc.'s stock has surged 13% recently, likely due to promising developments with its obesity injection, MariTide, which offers unique benefits over current treatments. MariTide's dual mechanism and less frequent dosing could enhance weight loss and diabetes management, potentially capturing a significant market share. Analysts project MariTide could generate $5 billion in peak annual revenue, bolstering Amgen's growth amidst competition from Eli Lilly, Novo Nordisk, and others. Despite competitive pressures and regulatory risks, MariTide's advancement into Phase 3 trials positions Amgen for mid-to-high single-digit revenue growth, making AMGN stock a "buy". Read the full article on Seeking AlphaSeeking Alpha • Feb 26
Amgen Stock: Why I Still Rate It A 'Buy'
Summary In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3, Tezspire achieved sales of $296 million in Q4 2024, an increase of 67.2% year-over-year. On the other hand, sales of Repatha, the flagship of Amgen's cardiovascular franchise, reached $606 million, an increase of 45.3% compared to the fourth quarter of 2023. In this article, dear Seeking Alpha readers, you will learn about additional factors that explain why I continue to cover AMGN stock with a 'Buy' rating. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$8b |
| Dec 31 2025 | US$25m | US$2m | US$8b |
| Sep 30 2025 | n/a | n/a | US$7b |
| Jun 30 2025 | n/a | n/a | US$7b |
| Mar 31 2025 | n/a | n/a | US$6b |
| Dec 31 2024 | US$24m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
報酬と市場: Bobの 総報酬 ($USD 24.69M ) は、 US市場 ($USD 14.80M ) の同規模の企業の平均を上回っています。
報酬と収益: Bobの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Bob Bradway (62 yo)
14yrs
在職期間
US$24,693,120
報酬
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and served as its President since May 2010 until May 2012. Mr. Bradway is responsible for the...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & CEO | 14yrs | US$24.69m | 0.11% $ 205.2m | |
| Executive VP & CFO | 6.3yrs | US$8.61m | 0.0074% $ 13.3m | |
| Executive VP & CTO | 2.4yrs | US$8.29m | 0.0062% $ 11.0m | |
| Executive Vice President of Global Commercial Operations | 7.7yrs | US$8.52m | 0.0076% $ 13.5m | |
| Executive Vice President of Research & Development | 1.4yrs | US$8.64m | 0.0013% $ 2.3m | |
| Executive Vice President of Operations | 9.8yrs | US$7.21m | 0.014% $ 24.9m | |
| Chief Accounting Officer & VP of Finance | 2.8yrs | データなし | 0.00058% $ 1.0m | |
| Senior VP & Chief Information Officer | 1.5yrs | データなし | データなし | |
| Senior VP of Global Research & Chief Scientific Officer | 1.4yrs | データなし | データなし | |
| Executive Director of Investor Relations | no data | データなし | データなし | |
| Executive VP | 10.8yrs | US$7.24m | 0.0059% $ 10.5m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 6.3yrs | データなし | 0.0011% $ 2.0m |
6.3yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: AMGNの経営陣は経験豊富で経験豊富です（平均在職期間は6.3年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & CEO | 14.6yrs | US$24.69m | 0.11% $ 205.2m | |
| Lead Independent Director | 13.4yrs | US$449.91k | 0.0013% $ 2.3m | |
| Co-Chair of the Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.8yrs | US$379.90k | 0.000080% $ 142.8k | |
| Independent Director | 9.3yrs | US$393.69k | 0.00023% $ 410.6k | |
| Independent Director | 12.6yrs | US$399.90k | 0.0024% $ 4.4m | |
| Independent Director | 9.6yrs | US$400.17k | 0.000080% $ 142.8k | |
| Independent Director | 8yrs | US$379.91k | 0.00040% $ 714.0k | |
| Independent Director | 14yrs | US$380.13k | 0.00064% $ 1.1m | |
| Independent Director | 8.4yrs | US$369.91k | 0.0014% $ 2.4m | |
| Member of Scientific Advisory Board of Cardiovascular & Metabolic | 2.3yrs | US$59.67k | データなし | |
| Co-Chair of the Scientific Advisory Board | less than a year | データなし | データなし |
9.3yrs
平均在職期間
69yo
平均年齢
経験豊富なボード: AMGNの 取締役会 は 経験豊富 であると考えられます ( 9.3年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 12:29 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Amgen Inc. 32 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。61
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |